Advertisement
Molecular and Cellular Pathobiology

A Novel Transgenic Mouse Model of the Human Multiple Myeloma Chromosomal Translocation t(14;16)(q32;q23)

Naoki Morito, Keigyou Yoh, Atsuko Maeda, Takako Nakano, Akiko Fujita, Manabu Kusakabe, Michito Hamada, Takashi Kudo, Kunihiro Yamagata and Satoru Takahashi
DOI: 10.1158/0008-5472.CAN-10-1057 Published January 2011

Abstract

Multiple myeloma (MM) is a currently incurable neoplasm of terminally differentiated B cells. The translocation and/or overexpression of c-MAF have been observed in human MM. Although c-MAF might function as an oncogene in human MM, there has been no report thus far describing the direct induction of MM by c-MAF overexpression in vivo. In this study, we have generated transgenic (TG) mice that express c-Maf specifically in the B-cell compartment. Aged c-Maf TG mice developed B-cell lymphomas with some clinical features that resembled those of MM, namely, plasma cell expansion and hyperglobulinemia. Quantitative RT-PCR analysis demonstrated that Ccnd2 and Itgb7, which are known target genes of c-Maf, were highly expressed in the lymphoma cells. This novel TG mouse model of the human MM t(14;16)(q32;q23) chromosomal translocation should serve to provide new insight into the role of c-MAF in tumorigenesis. Cancer Res; 71(2); 339–48. ©2011 AACR.

Introduction

Multiple myeloma (MM) is an incurable neoplasm of terminally differentiated B cells that is characterized by monoclonal expansion of malignant plasma cells. The common premalignant stage of MM is a monoclonal gammopathy of undetermined significance (MGUS), which progresses to MM at the rate of 1% of patients per year (1). Extensive genomic analysis has revealed that approximately 50% of patients with MGUS and MM have primary translocations in the clonal plasma cells that involve the immunoglobulin heavy chain (IGH) locus on chromosome 14q32 (2). Chromosomal translocations that involve the juxtaposition of the IGH locus with the loci for CCND1 (3), FGFR3 (4), or MMSET (5) result in the overexpression of these genes. It was first reported a decade ago that c-MAF is expressed at high levels in MM cells that carry the translocation t(14;16)(q32;q23), in which the IGH locus is fused with the c-MAF gene locus (6). In addition, c-MAF is overexpressed in 50% of MM cell lines and patients (7).

The maf proto-oncogene was identified originally within the genome of the avian musculoaponeurotic fibrosarcoma virus AS42 (8). The product of the Maf gene and other members of the Maf family share a conserved basic-region leucine zipper (bZIP) motif that mediates dimer formation and DNA binding to the Maf recognition element (MARE; ref. 9). Large Maf proteins, such as c-Maf, Mafb, Mafa/L-Maf/Smaf, and Nrl, also contain an acidic domain that mediates transcriptional activation and plays a key role in cellular differentiation (8–12). c-Maf encodes a T-helper cell type 2 (Th2)-specific transcription factor that activates the expression of interleukin (IL)-4 in T cells (13). It is also involved in the regulation of lens fiber cell differentiation (14–16). Recently, we have found that transgenic (TG) mice that express c-Maf specifically in the T-cell compartment develop T-cell lymphoma (17). Furthermore, 60% of human T-cell lymphomas, classified as angioimmunoblastic T-cell lymphomas, were found to overexpress c-MAF (17, 18).

On the basis of these facts, we hypothesized that overexpression of c-Maf in the B-cell lineage would enhance the development of an MM-like disease. In this study, we have generated c-Maf TG mice that overexpress c-Maf in the B-cell compartment, using the Igh promoter and Eμ enhancer. We found that these mice developed B-cell lymphoma, which provided the first direct evidence that c-Maf can function as an oncogene in a murine model of the t(14;16)(q32;q23) translocation.

Materials and Methods

Mice

We made 2 constructs for the Eμ c-Maf transgene (Fig. 1A). For construct-1, we used the Eμ enhancer and the VH promoter, as described previously (19). A 1.5-kb full-length cDNA that encoded the murine c-Maf protein was inserted into a vector that contained the VH promoter and Eμ enhancer. Construct-1 was injected into fertilized eggs from BDF1 mice to generate TG mice and then backcrossed 4 times into C57BL/6J. For construct-2, the VH promoter, Eμ enhancer, and 3′Eκ enhancer were used. Construct-2 was injected into fertilized eggs from C57BL/6J mice to generate TG mice. Mice were maintained with a C57BL/6J genetic background in specific pathogen-free conditions in a Laboratory Animal Resource Center. All experiments were carried out according to the Guide for the Care and Use of Laboratory Animals at the University of Tsukuba.

Figure 1.
Figure 1.

Generation of mice that overexpress c-Maf. A, constructs of the Eμ c-Maf transgene. The c-Maf cDNA was inserted into a vector that contained the VH gene promoter (Vp), and an Eμ enhancer (Eμ), or one that contained Vp, Eμ, and a 3′Eκ enhancer (Eκ). The probe for Southern blot analysis, the restriction enzyme sites (EcoRI; E, and HindIII; H), and the predicted sizes of the endogenous gene and the transgene are indicated. Transgene construct-1 was used for TG line 524, whereas TG lines 99 and 68 were generated with construct-2. B, a, Southern blot analysis of the endogenous and c-Maf TG genes in Eμ c-Maf TG mice. The 4.0-kb endogenous and 1.3-kb TG gene fragments are shown for TG mice. B, b, analysis of c-Maf mRNA in B cells. The amount of c-Maf mRNA in the samples from TG mice was higher than that in a sample from WT mice. B, c, Western blot analysis of splenic B220+ B cells from Eμ c-Maf TG mice (524, 99, and 68) and WT mice. C, immunofluorescence analysis of splenocyte subpopulations from Eμ c-Maf TG mice at 20 weeks of age. The total numbers of T cells (CD3+) and B cells (B220+) did not differ between the spleens of WT and Eμ c-Maf TG mice. There were no apparent differences in the subpopulations of B cells, namely, follicular cells (B220+CD23highCD21−) and marginal zone (MZ) B cells (B220+CD23−CD21high). D, proliferative potential of B cells after treatment with LPS. Enriched splenic B220+ cell populations obtained from WT and Eμ c-Maf TG mice at 20 weeks of age were cultured in the presence of LPS, and proliferation was assayed by using a CellTiter 96 AQueous One Solution Cell Proliferation Assay. The mean absorbance at 490 nm is presented.

Southern hybridization analysis

High-molecular-weight DNA was prepared from the tail of each mouse, and 10 μg of this DNA was digested with EcoRI and HindIII and then Southern hybridization was performed, as described previously (17). To investigate Igh gene rearrangement, DNA from the tail and other tissues was examined by Southern hybridization. DNA that had been digested with EcoRI was hybridized with the JH4 fragment, as described previously (20).

Isolation of mouse B220+ cells and reverse transcriptase PCR to analyze transgene expression

B220+ splenic B cells were isolated using magnetic microbeads from Miltenyi Biotec. Total RNA was prepared from the B220+ splenic B cells of 10 weeks old TG mice or their wild-type (WT) littermates using TRIzol reagent according to the manufacturer's instructions (Invitrogen). Total RNA (1 μg) was reverse transcribed into cDNA using SuperScript III Reverse Transcriptase (Invitrogen), and 1 μL of this 20 μL reaction mixture was used for PCR. The c-Maf sequence was amplified using the primers 5′-CCTGCCGCTTCAAGAGGGTGC-3′ and 5′-TCGCGTGTCACACTCACATG-3′, which yielded a 225-bp product. The sequence of Hprt (hypoxanthine-guanine phosphoribosyl transferase), which was used as a control, was amplified using the primers 5′-CAAACTTTGCTTTCCCTGGT-3′ and 5′-CAAGGGCATATCCAACAACA-3′, which yielded a 250-bp product.

Western blot analysis

Nuclear extracts were prepared from the B220+ splenic B cells of 10 weeks old TG or WT mice. The extracts were fractionated by size on a 10% SDS-polyacrylamide gel, transferred to a polyvinylidene difluoride membrane (Fluoro Trans; Pall BioSupport Division), and incubated with primary and secondary antibodies. To detect the c-Maf protein, a rabbit antibody against mouse c-Maf was used as the primary antibody and peroxidase-conjugated goat anti-rabbit IgG (Zymed Laboratories) was used as the secondary antibody. The anti-c-Maf antibody was kindly provided by Dr Masaharu Sakai (University of Hokkaido, Sapporo, Japan). To normalize the results with respect to the amount of protein in each sample, a goat antibody against mouse Lamin B (Santa Cruz Biochemicals) was used.

Flow cytometric analysis

Single-cell suspensions were prepared from the spleen and the bone marrow of each mouse. Multicolor flow cytometric analysis was performed using an LSR Flow Cytometer and CellQuest software (Becton Dickinson). The phycoerythrin (PE)-labeled rat antibodies against mouse CD3, CD138, CD23, and IgD, the FITC-labeled rat antibodies against mouse B220, CD21, and IgM, and APC-labeled rat antibody against mouse B220 were obtained from BD Pharmingen.

Cell culture of B cells

B220+ cells (2 × 105) were plated in triplicate on 96-well plates before stimulation with lipopolysaccharide (LPS; 10 μg/mL; Sigma) and anti-mouse CD40 (1 μg/mL; BD Pharmigen). After 16 hours of stimulation, the viable cell number was determined using a CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega). Aliquots of 40 μL of CellTiter 96 AQueous One Solution were added to each well and incubated for an additional 3 hours before the final absorbance at 490 nm was determined.

Measurement of serum immunoglobulins, paraprotein determination, and X-ray analysis

The amounts of IgG, IgM, and IgA were determined by ELISA, as described previously (21). Paraproteins (M spikes, extra gradients) were determined using cellulose acetate electrophoresis methods by SRL, Inc. X-ray analysis of bones was carried out using a Faxitron X-ray Specimen Radiographic System and Kodak X-OMAT-TL film.

Histopathologic analysis

Each mouse was bled under ether anesthesia. At autopsy, organs were fixed with 10% formalin in 0.01 mol/L phosphate buffer (pH 7.2) and embedded in paraffin. Sections were stained with hematoxylin and eosin (H&E) and periodic acid-Schiff (PAS) stain for histopathologic examination by light microscopy. For dual immunofluorescent staining, the rabbit antibody against mouse c-Maf, FITC-labeled goat anti-rabbit IgG (green), and PE-labeled rat anti-mouse CD138 antibody (red) were used. The anti-CD138 and anti-B220 antibodies were purchased from BD Pharmingen. The immunohistochemical analysis of CD138 and anti-B220 were performed by the avidin-biotin-peroxidase complex staining technique. For immunofluorescent analysis, frozen sections were stained with FITC-labeled goat antibodies against mouse immunoglobulins IgG, IgM, IgA, κ light chain, and λ light chain (ICN Pharmaceuticals).

Quantitative reverse transcriptase PCR

Total RNA (1 μg) was reverse transcribed into cDNA. Each reaction was done in duplicate. The quantity of cDNA in each sample was normalized to the amount of hprt cDNA. For the PCR, we used SYBR Premix Ex Taq II (TAKARA Bio) according to the manufacturer's instructions. The amplification was carried out in a Thermal Cycler Dice Real Time System (TAKARA Bio). The following primer pairs were used: c-Maf forward: 5′-CTGCCGCTTCAAGAGGGTGCAGC-3′ and c-Maf reverse: 5′-GATCTCCTGCTTGAGGTGGTC-3′; Ccnd2 forward: 5′-CCTCTTCTTCACACTTTTGTTGGTC-3′ and Ccnd2 reverse: 5′-CTACCTCCCGCAGTGTTCCT-3′; Itgb7 forward: 5′-CAACCTGGACTCACCCGAAG-3′ and Itgb7 reverse: 5′-CTACCTCCCGCAGTGTTCCT-3′; Prdm1 forward: 5′-AAGCCGAGGCATCCTTACC-3′ and Prdm1 reverse: 5′-GTCCAAAGCGTGTTCCCTTC-3′; Pax5 forward: 5′-ACAAACGCCAAAACCCTACC-3′ and Pax5 reverse: 5′-CTGCTGTACTTTTGTCCGAATGA-3′; Xbp1 forward: 5′-GGAGCAGCAAGTGGTGGATT-3′ and Xbp1 reverse: 5′-CAGCGTGTCCATTCCCAAG-3′: Myc forward: 5′-GATTTCCTTTGGGCGTTGG-3′ and Myc reverse: 5′-GAGGTCATAGTTCCTGTTGGTGAAG-3′; Irf4 forward: 5′-GGTGTACAGGATTGTTCCAGAGG-3′ and Irf4 reverse: 5′-GCAGAGAGCCATAAGGTGCTG-3′; Spp1 forward: 5′-GCTTGGCTTATGGACTGAGGT-3′ and Spp1 reverse: 5′-TCAGAAGCTGGGCAACAGG-3′; Hprt forward: 5′-TTGTTGTTGGATATGCCCTTGACTA-3′ and Hprt reverse: 5′-AGGCAGATGGCCACAGGACTA-3′.

Statistical analysis

Results were expressed as the mean ± SE. Data were compared by 1-way ANOVA and the Bonferroni correction was applied routinely. Significant differences between the groups of mice were analyzed using the Wilcoxon test for paired samples, and values of P < 0.05 were considered statistically significant. Survival rates were compared using the Kaplan–Meier method.

Results

Generation of Eμ c-Maf TG mice that express c-Maf specifically in B cells

To generate TG mice that express high levels of c-Maf specifically in B cells, the murine c-Maf coding sequence was inserted into a vector that contained the VH gene promoter, an Eμ enhancer sequence, and a 3′Eκ enhancer sequence (Fig. 1A). We generated 2 constructs (the first did not contain the 3′Eκ enhancer) and obtained 17 F0 TG mice with a BDF1 or C57BL/6J genetic background. Subsequently, 3 TG mouse lines with a C57BL/6J genetic background were generated and screened by PCR, using tail DNA as the template. Genomic DNA was analyzed by Southern blotting to confirm the integrity and copy number of the transgene in each TG line. The EcoRI/HindIII fragment that contained the c-Maf transgene was 1.3 kb in length, whereas the corresponding fragment for the endogenous c-Maf gene was 4.0 kb. The results of densitometric analyses revealed that TG line 524, which was generated using construct-1, contained approximately 4 copies of the transgene, whereas TG lines 99 and 68, which were generated with construct-2, both contained approximately 2 copies (Fig. 1B, a). These transgenes were stably transmitted to the progeny.

Overexpression of c-Maf in TG mice

To confirm that the transgene was expressed, the levels of c-Maf mRNA and protein in splenic B cells from the TG lines were monitored by reverse transcriptase PCR (RT-PCR) and Western blotting (Fig. 1B, b and c). The c-Maf mRNA was overexpressed in all the TG mice that were tested (Fig. 1B, b). Correspondingly, Western blot analysis of B220+ splenic B cells confirmed that the levels of c-Maf protein were elevated (Fig. 1B, c). c-Maf protein was not detected in WT B cells in this analysis.

B-cell development and proliferative potential in Eμ c-Maf TG mice

To investigate the effect of c-Maf overexpression on B-cell differentiation, we carried out flow cytometric analysis of splenocytes isolated from TG mice at 20 weeks of age. Flow cytometry showed that the total numbers of T cells (CD3+) and B cells (B220+) in the spleens of Eμ c-Maf TG mice were unaltered relative to WT mice (Fig. 1C). In addition, we could not find any apparent differences in the subpopulations of B cells, namely, follicular cells (B220+CD23highCD21−) and marginal zone (MZ) B cells (B220+CD23− CD21high; Fig. 1C). Next, we analyzed the proliferative potential of WT and Eμ c-Maf TG B cells in vitro. The proliferative potential of Eμ c-Maf TG B cells was relatively high, but there was no substantial difference in the response to LPS (Fig. 1D) or CD40 (data not shown) between the two groups.

Aged Eμ c-Maf TG mice developed lymphoma

The Eμ c-Maf TG mice appeared healthy up to 50 weeks of age. However, they subsequently developed tumors. The mean age at diagnosis as lymphoma by histologic analysis was 80.1 weeks. We confirmed that 28% (18/64) of the Eμ c-Maf TG mice developed lymphoma (Fig. 2A). We could not detect any apparent difference in survival between the mice that were generated with the two different constructs, construct-1 for TG524 and construct-2 for TG 99 and 68.

Figure 2.
Figure 2.

Eμ c-Maf TG mice developed B-cell lymphoma. A, cumulative lymphoma-free survival rate curves of Eμ c-Maf TG and WT mice. Statistically significant differences (P 0.05) were detected between the two groups. B, the number of plasma cell-like lymphoma cells in the spleens of Eμ c-Maf TG mice was increased compared with that in the controls (WT). Disruption of the normal follicles and accumulation of lymphoma cells were observed in spleens from the TG mice (H&E). C, the B-cell lymphoma cells (B220+) also expressed CD138, as shown by immunohistochemical staining of B220 and CD138. Immunofluorescence showed that plasma cells (CD138+, red) that had infiltrated into the spleens of Eμ c-Maf TG mice also expressed c-Maf (green), but this was not observed in the spleens of WT mice. Flow cytometry revealed that the number of B220+CD138+ cells was increased in the spleens of Eμ c-Maf TG mice that carried lymphoma. The number of mature plasma cells (B220lowCD138+) in the spleen was also increased. D, B220+CD138+ cells in the spleens of Eμ c-Maf TG mice were characterized as B220+CD138+CD21+CD23+IgM+IgD− by flow cytometry.

Lymphomas observed in Eμ c-Maf TG mice were of B-cell origin

Eμ c-Maf TG mice appeared healthy up to 50 weeks of age, but they developed tumors subsequently. We performed histologic analysis to identify the origin of the lymphoma cells. The spleens of the Eμ c-Maf TG mice were enlarged approximately 2- to 5-fold relative to those of the WT mice. The spleens of the mice with lymphoma were infiltrated by numerous cells, which partially destroyed the normal tissue architecture (Fig. 2B). Cells that had infiltrated showed plasma cell-like morphology (Fig. 2B). Moreover, immunohistochemical analysis revealed that the infiltrating cells were B220+ (Fig. 2C) and also expressed CD138 (Fig. 2C). We confirmed that the infiltrating cells were positive for both CD138 and c-Maf by immunofluorescence staining (Fig. 2C). To investigate the characteristics of the lymphoma cells, we performed flow cytometry (Fig. 2C and D). We found the number of B220+CD138+CD21+CD23+IgM+IgD− cells was increased in the TG mice relative to the WT mice. We also found that the number of mature plasma cells (B220lowCD138+) was increased in the TG mice (Fig. 2C).

Hypergammmaglobulinemia in aged Eμ c-Maf TG mice

Approximately 50% (7/14) of the Eμ c-Maf TG mice of line 524 showed a clonal M spike in the serum between 20 and 50 weeks of age (Fig. 3A). At 120 weeks old, 35% (5/14) of these TG mice had developed lymphoma. The remaining mice that showed a clonal M spike (2/14) showed no evidence of lymphoma at 120 weeks. The plasma levels of both IgG and IgM, as measured by ELISA, were increased significantly in aged Eμ c-Maf TG mice (Fig. 3B). The mean amount of total IgG in the TG mice was 1,760 ± 302 (mg/dL), whereas in the control mice this value was 934 ± 142 (mg/dL; P < 0.05). In addition, the mean amount of total IgM in the TG mice was 1,083 ± 223 (mg/dL), whereas in the control mice this value was 564 ± 92 (mg/dL). However, there was no obvious elevation of total IgA in the TG mice. It must be noted that only 1 of the 14 mice showed high levels of both IgG and IgM (Fig. 3B). Notably, these changes in the serum were associated with increased numbers of mature plasma cells (B220low CD138+) in the bone marrow; the proportion of plasma cells as a percentage of the total number of bone marrow cells was about 5% to 20% in the TG mice compared with less than 5% in the non-TG controls (Fig. 3C). We also found the number of B220+CD138+ cells in the bone marrow was increased (Fig. 3C). However, we could not identify any obvious osteolytic lesions by X-ray analysis (Fig. 3C).

Figure 3.
Figure 3.

Hypergammaglobulinemia, bone marrow plasmacytic infiltration, and X-ray analysis of the bones in Eμ c-Maf TG mice. A, representative results of electrophoresis of the serum proteins. Note the presence of an M spike (arrow) in Eμ c-Maf TG mice at 50 weeks old. B, marked elevation of serum immunoglobulin levels in Eμ c-Maf TG mice. Sera from WT (○; n = 7) and Eμ c-Maf TG (TG; •; n = 14) mice at 50 weeks old were analyzed by ELISA (top). The plot shows both IgG and IgM levels in Eμ c-Maf TG mice at 50 weeks old. Only 1 of the 14 mice showed high levels of both IgG and IgM (bottom). C, representative bone marrow biopsies from WT and Eμ c-Maf TG mice were analyzed by light microscopy (H&E) to reveal increased plasma cell infiltrates in the marrow of Eμ c-Maf TG mice. FACS analysis also revealed that the numbers of mature plasma cells (B220lowCD138+) and B220+CD138+ cells were increased in the bone marrow in the TG mice. Obvious osteolytic lesions could not be found in 50 weeks old Eμ c-Maf TG mice by X-ray analysis.

Eμ c-Maf TG mice showed clinical features that resembled those of patients with plasma cell disorders

In Eμ c-Maf TG mice with hyperglobulinemia that were older than 60 weeks, renal tubular casts and tubular obstruction were observed (Fig. 4A), which resembled human myeloma kidney (so-called cast nephropathy; ref. 22). Moreover, glomerular changes that were characterized by mesangial widening due to the deposition of PAS-positive material were observed in aged Eμ c-Maf TG mice (Fig. 4A); this resembled monoclonal immunoglobulin deposition disease (22). These renal lesions were similar to the pathologic manifestations that are present in human MM and other plasma cell disorders in which the systemic chronic overproduction of immunoglobulins and the accumulation of light chains, paraproteins, and other immunoglobulin fragments are observed (22). The depositions contained immunoglobulin light and heavy chains, which consisted of either polyclonal heavy and light chains or clonal IgG or IgM heavy chains and κ light chains (Fig. 4B).

Figure 4.
Figure 4.

Renal involvement in Eμ c-Maf TG mice. A, renal tissue sections from 60 weeks old Eμ c-Maf TG mice with lymphoma and WT mice were stained with PAS. Left, renal tubules; right, glomeruli. B, glomerular immunoglobulin deposition. Serial frozen sections of renal tissue from WT and Eμ c-Maf TG mice were analyzed by immunofluorescent staining using specific antibodies against mouse immunoglobulin κ and λ light chains, as well as antibodies against IgG, IgM, and IgA heavy chains.

Autonomous proliferation in nude mice of lymphoma cells from Eμ c-Maf TG mice

To ascertain whether the infiltrating tumor cells in Eμ c-Maf TG mice could proliferate autonomously, we isolated mononuclear cells from the spleens of these mice and injected the isolated cells into nude mice via the tail vein (106 cells per mouse). Recipient mice displayed prominent hepatomegaly, splenomegaly, and/or enlarged lymph nodes throughout their bodies within 12 weeks of transplantation. A typical example is shown in Figure 5A. The tumor cells could also be transplanted into syngeneic C57BL/6J mice. To assess clonality, we examined the rearrangement of the Igh locus in the c-Maf TG lymphoma cells. Southern blot analysis was carried out using a murine JH4 probe (Fig. 5B). We extracted DNA from the tails and spleens of the mice. Monoclonal rearrangement of the Igh locus was found in DNA that had been isolated from the spleens of the Eμ c-Maf TG mice (Fig. 5B, lanes 3–6). Histologic analysis of the spleen from these recipient mice revealed that the tumor cells showed a plasma cell-like morphology, that is, the same as the original lymphoma cells (Fig. 5C).

Figure 5.
Figure 5.

Autonomous proliferation of c-Maf–induced lymphoma cells. A, mononuclear cells that had been isolated from the spleens of Eμ c-Maf TG mice and transplanted into nude mice infiltrated the spleens of the recipient mice. Enlarged liver and spleen were observed in the recipient mouse. B, Southern blot analyses of lymphoma cells from the spleens of Eμ c-Maf TG mice using a JH4 probe after digestion with EcoRI. Lane 1 (DNA from tail of a WT mouse), lane 2 (DNA from the tail of an Eμ c-Maf TG mouse), and lanes 3 to 6 (DNA from the enlarged spleens from Eμ c-Maf TG mice) show the presence of a DNA fragment corresponding to the germ line JH4 gene (solid arrow). Lanes 3 to 6 show DNA fragments that corresponded to rearrangements of the Igh gene (asterisk). Lanes 2 to 6 show a DNA fragment that corresponded to the Igh transgene (hollow arrow). C, transplanted tumor cells showed a plasma cell–like appearance in the spleens of the recipients, as shown by H&E staining.

Expression of c-Maf target genes in Eμ c-Maf TG mice

To gain insight into the molecular mechanism by which plasma cell dyscrasia develops, we measured the level of mRNA expression from c-Maf and its target genes in Eμ c-Maf TG mice, using a quantitative RT-PCR assay (Fig. 6). In human MM, CCND2 and ITGB7 are known to be targets of c-MAF (7, 23). As we have described previously, deregulated expression of Ccnd2 and Itgb7 is also observed in the T-cell lymphomas of TG mice that overexpress c-Maf in the T-lymphoid compartment (17). Therefore, we analyzed the expression of Ccnd2 and Itgb7 in Eμ c-Maf TG mice. The level of c-Maf expression in the lymphoma-infiltrated lymph nodes of Eμ c-Maf TG mice was 3- to 5-fold greater than the level in WT B cells (B220+; Fig. 6). We confirmed the percentage of B220+ cells in the lymph nodes was more than 70%. We also found that the expression of both Ccnd2 and Itgb7 was elevated in Eμ c-Maf TG mice (Fig. 6), which was consistent with the results of previous reports in human MM (7).

Figure 6.
Figure 6.

Analysis of c-Maf target genes by quantitative RT-PCR. The expression profiles of Maf (c-Maf) and its target genes were examined by real-time RT-PCR analysis. Total RNA was obtained from the enlarged lymph nodes from Eμ c-Maf TG mice. All of the data are presented as the mean ± SE. □, WT; mRNA from B220+ B cells from the spleens of 50 weeks old WT mice; ▪, TG; mRNA from the lymph nodes of mice from Eμ c-Maf TG line 524. *, P < 0.05.

Next, we examined the levels of the B-cell–associated transcription factors, Prdm1 (Blimp-1), Xbp1, and Pax5. Blimp-1 is a transcriptional repressor that plays a critical role in the terminal differentiation of B cells into antibody-secreting plasma cells (24). Overexpression of Blimp-1 has been shown to drive plasma cell differentiation (24–26). Xbp1 is a bZIP transcription factor and a major regulator of plasma cell differentiation (27). It is known that Eμ Xbp1s mice develop MM/MGUS (28). In addition, Pax5 is known to inhibit plasmacytic development and also to repress the expression of Xbp1, which is needed for plasma cell formation and immunoglobulin secretion (29). By RT-PCR analysis (Fig. 6), we found that Prdm1 and Xbp1 expression were increased but Pax5 expression was decreased in the TG mice as compared with the control mice, which might correlate with the plasma cell differentiation.

It is known that the dysregulation of MYC (c-MYC) expression can induce the progression of MGUS to MM (1). In addition, it has been reported that myeloma cells are completely dependent on the transcription factor IRF4 (interferon regulatory factor 4), despite that fact that most myeloma cells do not harbor mutations, translocations, or amplifications of the IRF4 locus (30). Moreover, IRF4 itself is a direct target of MYC that generates an autoregulatory circuit in myeloma cells (30). However, neither Myc nor Irf4 expression was elevated in the Eμ c-Maf TG mice. We also analyzed Spp1 (osteopontin) expression, because we could not find any obvious osteolytic lesions in the Eμ c-Maf TG mice. SPP1, which is highly expressed in MM, plays a critical role in bone disease by protecting the bone from destruction (31). We observed that the expression of Spp1 was upregulated in Eμ c-Maf TG mice (Fig. 6).

Discussion

It is important to emphasize that v-maf is a classical oncogene that was identified in an avian transforming virus, AS42 (8). Large Maf proteins, such as c-Maf, Mafb and Mafa, can efficiently transform primary fibroblasts in vitro (9, 32–34). Previously, we generated c-Maf TG mice that overexpress c-Maf in the T-cell compartment, using the VA vector that contains the human CD2 promoter and locus control region. The VA c-Maf TG mice developed T-cell lymphoma, thus providing evidence that c-Maf can function as an oncogene in T cells in vivo (17). Work over the last decade has provided evidence that c-MAF might play crucial roles in the pathogenesis of MM. It has been reported that the translocation and/or overexpression of c-MAF are identified frequently in human MM (6, 7, 23). Translocations that involve MAFA (23, 35) or MAFB [t(14;20)(q32;q12); refs. 35, 36], which encode other large MAF proteins, have also been identified. Altogether, translocations that involve a large MAF transcription factor are found in 8% to 10% of MMs: c-MAF is translocated in 5%, MAFB in 2%, and MAFA in less than 1% of cases (23, 35). Although c-MAF translocations are observed in only 5% to 10% of MMs, c-MAF is overexpressed in 50% of cases (7, 23).

In this study, we demonstrated that aged c-Maf TG mice developed B-cell lymphomas with some clinical features that resembled those of human MM, namely, expansion of plasma cells, hyperglobulinemia, and renal involvement. Although we found that plasma cells (B220lowCD138+) were increased in the spleen and bone marrow of the TG mice, the lymphoma cells in the spleens were B220+CD138+CD21+CD23+IgM+IgD−. The phenotype of some Eμ c-Maf TG mice partially resembled that of types of B-cell lymphoma that contain plasmablasts and/or plasma cells rather than plasma cell dyscrasias, such as Waldenström's macroglobulinemia (WM; also known as lymphoplasmacytic lymphoma) or MALT (mucosa-associated lymphoid tissue) lymphoma. WM is classified as an indolent form of B-cell lymphoma. Infiltration with clonal lymphoplasmacytic cells, predominantly in the bone marrow, and an IgM monoclonal gammopathy are diagnostic findings of WM (37). MALT lymphoma is a distinct subtype of MZ B-cell lymphomas. The large number of plasma cells among MALT lymphoma cells is a well-known phenomenon known as plasmacytic differentiation (38). With the demonstration that the tumors express both mature B-cell (B220+) and plasma cell (CD138+) markers, it should be noted that they fall within a spectrum of mouse plasma cell–related tumors (anaplastic, plasmablastic, and plasmacytic plasmacytoma) described previously (39, 40, 41). The Eμ c-Maf TG mouse is a murine model of the human MM t(14;16)(q32;q23) chromosomal translocation. Primary early-onset reciprocal chromosomal translocations in MM occur most frequently at IGH on 14q32. Meanwhile, secondary late-onset translocations and gene mutations have been implicated in MM progression (42). The fact that Eμ c-Maf TG mice displayed immature phenotypes rather than classical MM might suggest that c-MAF translocation alone is not sufficient for the development of classical MM. Experimental efforts to generate mouse models of MM have typically involved the targeted expression of an oncogene in the B-cell compartment by TG approaches (28). These strategies have generally yielded B-cell malignancies that display immature phenotypes or plasmacytomas rather than classical MM (28). Given that c-MAF is known to be translocated and/or overexpressed in human MM, the Eμ c-Maf TG mouse may offer an ideal system to study the pathogenesis of human MM. Aged Eμ c-Maf TG mice developed B-cell lymphomas rather than plasma cell dyscrasias. In the majority of cases, TG mice that express an oncogene or proto-oncogene specifically in the B-cell compartment develop plasmacytoma and not classical MM. This is the case for v-abl (43), Il-6 (44), and Bcl-2/c-Myc (45) mice; however, Eμ Xbp1s (28) TG mice are the exception. Recently, it was reported that TG mice in which the c-Myc gene was subject to conditional Aid (activation-induced deaminase)-dependent activation developed the MM/MGUS phenotype (46). We do not understand the underlying differences in the promotion of tumor formation between mice and humans.

Further studies will be needed to define the role of c-Maf in the development of both human and mouse MM. Clarification of the mechanism by which c-Maf contributes to oncogenesis may ultimately facilitate the discovery of more specific therapies to prevent the progression of MM.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Grant Support

A grant-in-aid for Scientific Research on Priority Areas and Genome Network Project from the Ministry of Education, Culture, Sports, Science, and Technology, Japan, a grant-in-aid for Exploratory Research (22650090), a grant from The Naito Foundation, and a grant from the Astellas Foundation for Research on Metabolic Disorders.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • Received March 26, 2010.
  • Revision received September 17, 2010.
  • Accepted November 2, 2010.

References

  1. 1.↵
    1. Kyle RA,
    2. Rajkumar SV
    . Multiple myeloma. N Engl J Med 2004;351:1860–73.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Sirohi B,
    2. Powles R
    . Epidemiology and outcomes research for MGUS, myeloma and amyloidosis. Eur J Cancer 2006;42:1671–83.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Chesi M,
    2. Bergsagel PL,
    3. Brents LA,
    4. Smith CM,
    5. Gerhard DS,
    6. Kuehl WM
    . Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood 1996;88:674–81.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Chesi M,
    2. Nardini E,
    3. Brents LA,
    4. Schröck E,
    5. Ried T,
    6. Kuehl WM,
    7. et al.
    Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 1997;16:260–4.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Chesi M,
    2. Nardini E,
    3. Lim RS,
    4. Smith KD,
    5. Kuehl WM,
    6. Bergsagel PL
    . The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 1998;92:3025–34.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Chesi M,
    2. Bergsagel PL,
    3. Shonukan OO,
    4. Martelli ML,
    5. Brents LA,
    6. Chen T,
    7. et al.
    Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood 1998;91:4457–63.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Hurt EM,
    2. Wiestner A,
    3. Rosenwald A,
    4. Shaffer AL,
    5. Campo E,
    6. Grogan T,
    7. et al.
    Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cells 2004;5:191–9.
    OpenUrlCrossRef
  8. 8.↵
    1. Nishizawa M,
    2. Kataoka K,
    3. Goto N,
    4. Fujiwara KT,
    5. Kawai S
    . v-maf, a viral oncogene that encodes a “leucine zipper” motif. Proc Natl Acad Sci U S A 1989;86:7711–5.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Kataoka K,
    2. Noda M,
    3. Nishizawa M
    . Maf nuclear oncoprotein recognizes sequences related to an AP-1 site and form heterodimers with both Fos and Jun. Mol Cell Biol 1994;14:700–12.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Swaroop A,
    2. Xu J,
    3. Pawar H,
    4. Jackson A,
    5. Skolnick C,
    6. Agarwal N
    . A conserved retina-specific gene encodes a basic motif/leucine zipper domain. Proc Natl Acad Sci USA 1992;89:266–70.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Ogino H,
    2. Yasuda K,
    3. et al.
    Induction of lens differentiation by activation of a bZIP transcription factor, L-Maf. Science 1998;280:115–8.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Kajihara M,
    2. Kawauchi S,
    3. Kobayashi M,
    4. Ogino H,
    5. Takahashi S,
    6. Yasuda K
    . Isolation, characterization, and expression analysis of zebrafish large Mafs. J Biochem 2001;129:139–46.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Ho IC,
    2. Hodge MR,
    3. Rooney JW,
    4. !Glimcher LH
    . The proto-oncogene c-maf is responsible for tissue-specific expression of interleukin-4. Cell 1996;85:973–83.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Kawauchi S,
    2. Takahashi S,
    3. Nakajima O,
    4. Ogino H,
    5. Morita M,
    6. Nishizawa M,
    7. et al.
    Regulation of lens fiber cell differentiation by transcription factor c-Maf. J Biol Chem 1999;274:19254–60.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Kim JI,
    2. Li T,
    3. Ho IC,
    4. Grusby MJ,
    5. Glimcher LH
    . Requirement for the c-Maf transcription factor in crystallin gene regulation and lens development. Proc Natl Acad Sci U S A 1999;96:3781–5.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Ring BZ,
    2. Cordes SP,
    3. Overbeek PA,
    4. !Barsh GS
    . Regulation of mouse lens fiber cell development and differentiation by the Maf gene. Development 2000;127:307–17.
    OpenUrlAbstract
  17. 17.↵
    1. Morito N,
    2. Yoh K,
    3. Fujioka Y,
    4. Nakano T,
    5. Shimohata H,
    6. Hashimoto Y,
    7. et al.
    Overexpression of c-Maf contributes to T-cell lymphoma in both mice and human. Cancer Res 2006;66:812–9.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Murakami YI,
    2. Yatabe Y,
    3. Sakaguchi T,
    4. Sasaki E,
    5. Yamashita Y,
    6. Morito N,
    7. et al.
    c-Maf expression in angioimmunoblastic T-cell lymphoma. Am J Surg Pathol 2007;31:1695–702.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Nagaoka H,
    2. Takahashi Y,
    3. Hayashi R,
    4. Nakamura T,
    5. Ishii K,
    6. Matsuda J,
    7. et al.
    Ras mediates effector pathways responsible for pre-B cell survival, which is essential for the developmental progression to the late pre-B cell stage. J Exp Med 2000;192:171–82.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Costinean S,
    2. Zanesi N,
    3. Pekarsky Y,
    4. Tili E,
    5. Volinia S,
    6. Heerema N,
    7. et al.
    Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A 2006;103:7024–9.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Morito N,
    2. Yoh K,
    3. Hirayama A,
    4. Itoh K,
    5. Nose M,
    6. Koyama A,
    7. et al.
    Nrf2 deficiency improves autoimmune nephritis caused by the fas mutation lpr. Kidney Int 2004;65:1703–13.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Korbet SM,
    2. Schwartz MM
    . Multiple myeloma. J Am Soc Nephrol 2006;17:2533–45.
    OpenUrlFREE Full Text
  23. 23.↵
    1. Eychène A,
    2. Rocques N,
    3. Pouponnot C
    . A new MAFia in cancer. Nat Rev Cancer 2008;8:683–93.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Turner CA Jr,
    2. Mack DH,
    3. Davis MM
    . Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells. Cell 1994;77:297–306.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Schliephake DE,
    2. Schimpl A
    . Blimp-1 overcomes the block in IgM secretion in lipopolysaccharide/anti-muF(ab')2-co-stimulated B lymphocytes. Eur J Immunol 1996;26:268–71.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Piskurich JF,
    2. Lin KI,
    3. Lin Y,
    4. Wang Y,
    5. Ting JP,
    6. Calame K
    . BLIMP-I mediates extinction of major histocompatibility class II transactivator expression in plasma cells. Nat Immunol 2000;1:526–32.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Reimold AM,
    2. Ponath PD,
    3. Li YS,
    4. Hardy RR,
    5. David CS,
    6. Strominger JL,
    7. et al.
    Transcription factor B cell lineage-specific activator protein regulates the gene for human X-box binding protein 1. J Exp Med 1996;183:393–401.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Carrasco DR,
    2. Sukhdeo K,
    3. Protopopova M,
    4. Sinha R,
    5. Enos M,
    6. Carrasco DE,
    7. et al.
    The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cells 2007;11:349–60.
    OpenUrlCrossRef
  29. 29.↵
    1. Reimold AM,
    2. Iwakoshi NN,
    3. Manis J,
    4. Vallabhajosyula P,
    5. Szomolanyi-Tsuda E,
    6. Gravallese EM,
    7. et al.
    Plasma cell differentiation requires the transcription factor XBP-1. Nature 2001;412:300–7.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Shaffer AL,
    2. Emre NC,
    3. Lamy L,
    4. Ngo VN,
    5. Wright G,
    6. Xiao W,
    7. et al.
    IRF4 addiction in multiple myeloma. Nature 2008;454:226–31.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Robbiani DF,
    2. Colon K,
    3. Ely S,
    4. Chesi M,
    5. Bergsagel PL
    . Osteopontin dysregulation and lytic bone lesions in multiple myeloma. Hematol Oncol 2007;25:16–20.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Kataoka K,
    2. Nishizawa M,
    3. Kawai S
    . Structure-function analysis of the maf oncogene product, a member of the b-Zip protein family. J. Virol 1993;67:2133–41.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    1. Nishizawa M,
    2. Kataoka K,
    3. Vogt PK
    . MafA has strong cell transforming ability but is a weak transactivator. Oncogene 2003;22:7882–90.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Pouponnot C,
    2. Sii-Felice K,
    3. Hmitou I,
    4. Rocques N,
    5. Lecoin L,
    6. Druillennec S,
    7. et al.
    Cell context reveals a dual role for Maf in oncogenesis. Oncogene 2006;25:1299–310.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Chng WJ,
    2. Glebov O,
    3. Bergsagel PL,
    4. !Kuehl WM
    . Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol 2007;20:571–96.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Hanamura I,
    2. Iida S,
    3. Akano Y,
    4. Hayami Y,
    5. Kato M,
    6. Miura K,
    7. et al.
    Ectopic expression of MAFB gene in human myeloma cells carrying (14;20)(q32;q11) chromosomal translocations. Jpn J Cancer Res 2001;92:638–44.
    OpenUrlCrossRef
  37. 37.↵
    1. Strasser A,
    2. Pascual V
    . Pathophysiology of Waldenström's macroglobulinemia. Haematologica 2010;95:359–64.
    OpenUrlFREE Full Text
  38. 38.↵
    1. Cohen SM,
    2. Petryk M,
    3. Varma M,
    4. Kozuch PS,
    5. Ames ED,
    6. Grossbard ML
    . Non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue. Oncologist 2006;11:1100–17.
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    1. Qi CF,
    2. Zhou JX,
    3. Lee CH,
    4. Naghashfar Z,
    5. Xiang S,
    6. Kovalchuk AL,
    7. et al.
    Anaplastic, plasmablastic, and plasmacytic plasmacytomas of mice: relationships to human plasma cell neoplasms and late-stage differentiation of normal B cells. Cancer Res 2007;67:2439–47.
    OpenUrlAbstract/FREE Full Text
  40. 40.↵
    1. Qi CF,
    2. Shin DM,
    3. Li Z,
    4. Naghashfar Z,
    5. Xiang S,
    6. Kovalchuk AL,
    7. et al.
    Anaplastic plasmacytomas: relationships to normal memory B cells and plasma cell neoplasms of immunodeficient and autoimmune mice. J Pathol 2010;221:106–16.
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Ishikawa F,
    2. Saito Y,
    3. Shultz LD
    . Modeling human leukemia using immune-compromised mice. In: Li S, editor. Mouse Models of Human Blood Cancers. New York: Springer; 2008. p.121–9.
  42. 42.↵
    1. Raab MS,
    2. Podar K,
    3. Breitkreutz I,
    4. Richardson PG,
    5. Anderson KC
    . Multiple myeloma. Lancet 2009;374:324–39.
    OpenUrlCrossRefPubMed
  43. 43.↵
    1. Rosenbaum H,
    2. Harris AW,
    3. Bath ML,
    4. McNeall J,
    5. Webb E,
    6. Adams JM,
    7. et al.
    An E mu-v-abl transgene elicits plasmacytomas in concert with an activated myc gene. EMBO J 1990;9:897–905.
    OpenUrlPubMed
  44. 44.↵
    1. Suematsu S,
    2. Matsusaka T,
    3. Matsuda T,
    4. Ohno S,
    5. Miyazaki J,
    6. Yamamura K,
    7. et al.
    Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice. Proc Natl Acad Sci U S A 1992;89:232–5.
    OpenUrlAbstract/FREE Full Text
  45. 45.↵
    1. Strasser A,
    2. Harris AW,
    3. Bath ML,
    4. !Cory S
    . Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 1990;348:331–3.
    OpenUrlCrossRefPubMed
  46. 46.↵
    1. Chesi M,
    2. Robbiani DF,
    3. Sebag M,
    4. Chng WJ,
    5. Affer M,
    6. Tiedemann R,
    7. et al.
    AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cells 2008;13:167–80.
    OpenUrlCrossRef
Back to top
Cancer Research: 71 (2)
January 2011
Volume 71, Issue 2

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Email Article
Citation Tools
A Novel Transgenic Mouse Model of the Human Multiple Myeloma Chromosomal Translocation t(14;16)(q32;q23)
Naoki Morito, Keigyou Yoh, Atsuko Maeda, Takako Nakano, Akiko Fujita, Manabu Kusakabe, Michito Hamada, Takashi Kudo, Kunihiro Yamagata and Satoru Takahashi
Cancer Res January 15 2011 (71) (2) 339-348; DOI: 10.1158/0008-5472.CAN-10-1057
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section

Advertisement